Coherent Market Insights

Human Papillomavirus (HPV) And Cytomegalovirus (CMV) Therapeutics Market to Surpass US$ 4.8 Billion by 2026

Human Papillomavirus (HPV) And Cytomegalovirus (CMV) Therapeutics Market to Surpass US$ 4.8 Billion by 2026 - Coherent Market Insights

Publish In: Jun 14, 2019

The Global Human Papillomavirus (HPV) and Cytomegalovirus(CMV) Therapeutics Market, by Drug Type (HPV Therapeutics (Immunomodulatory Agents, Keratolytic Agents, Anti-Neoplastic Agents, and Sinecatechins) and CMV Therapeutics (Ganciclovir/Valaganciclovir, Foscarnet, and  Cidifovir), by Application (HPV Therapeutics- Genital warts, Cervical cancer, Epidermodysplasia Verrucifdormis, and Others) and (CMV Therapeutics-CMV Retinitis, Pneumonia, Gastrointestinal Ulcers, Encephalitis, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 3,006.4 million in 2018, and is projected to exhibit a CAGR of 6.0%, during the forecast period (2018 - 2026), as highlighted in a new report published by Coherent Market Insights.

Cytomegalovirus (CMV) is also known as Human Herpes Virus 5 (HHV-5). This virus is most commonly transmitted to a developing fetus. It affects males and females equally at any age. For instance, in January 2018, according to Centers for Disease Control and Prevention (CDC), around 50% adults suffer from CMV infections in U.S. Increasing approval activities for novel therapies is expected to drive the market growth. For instance, in January 2016, Fate Therapeutics Inc. received approval from the U.S. Food and Drug Administration for its new programmed cellular immunotherapy ProTmune. It is used for prevention of acute CMV infection and GvHD (Graft- versus-Host Disease) infection.

Browse 37 Market Data Tables and 33 Figures spread through 167 Pages and in-depth TOC on " Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market, by Drug Type (HPV Therapeutics (Immunomodulatory Agents, Keratolytic Agents, Anti-Neoplastic Agents, and Sinecatechins) and CMV Therapeutics (Ganciclovir/Valaganciclovir, Foscarnet, and  Cidifovir), by Application (HPV Therapeutics- Genital warts, Cervical cancer, Epidermodysplasia Verrucifdormis, and Others) and (CMV Therapeutics-CMV Retinitis, Pneumonia, Gastrointestinal Ulcers, Encephalitis, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"

To know the latest trends and insights related to Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/human-papillomavirus-hpv-and-cytomegalovirus-cmv-therapeutics-market-2707

Consistent research and development activities for the treatment of HPV and CMV infections is expected to boost the human papillomavirus and cytomegalovirus therapeutics market growth during the forecast period. For instance, in May 2014, Atara Biotherapeutics initiated clinical study of preemptive adoptive CMV-specific T cells (CMVpp65) infusion for prevention of refractory CMV infection in patients. These cells can restore antiviral immunity and clear CMV infection after allogeneic hematopoietic stem cell transplantation. This study is expected to complete in June 2019.

Furthermore, in July 2012, University of Alabama at Birmingham initiated clinical phase II study of quadrivalent HPV recombinant vaccine. It is used for the treatment of HPV (types 6, 11, 16, 18) infections. This study is expected to complete in November 2020. In January 2018, Shire Company received approval from the U.S. Food and Drug Administration for its new investigational treatment drug Maribavir (SHP620). This drug is used for the treatment of CMV infections.

Key Takeaways of the Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market:

  • The global Human Papillomavirus (HPV) and Cytomegalovirus (CMV) therapeutics market is expected to witness a CAGR of 6.0% during the forecast period (2018 – 2026), owing to increasing prevalence of cervical cancer in U.S. For instance, according to WHO (World Health Organization) report 2018, around 570,000 women suffer from cervical cancer and in 2018 around 311000 women died from cervical cancer worldwide.
  • Among regions, North America is expected to hold largest market share for human papillomavirus (HPV) and cytomegalovirus (CMV) market, owing to increasing approval activities by the U.S. Food and Drug Administration. For instance, in June 2018, the U.S. Food and Drug Administration announced approval of Keytruda (Contains-Pembrolizumab), which is used for the treatment of PD-L1–positive cervical cancer.
  • Major players operating in the global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market include, Allergan, Bausch Health, GlaxoSmithKline, Lee’s Pharmaceutical Holdings, Merck Sharp & Dohme, Fougera Pharmaceuticals, Clinigen Group plc., Perrigo Company plc., Roche Holding AG, Biotest AG, and Fresenius Kabi

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports


Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail


Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Created billion dollars of revenue impact on thousands of clients

trusted clients logo
LogoCredibility and Certifications

Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.

Reliability and Reputation

860519526

Reliability and Reputation
Reliability and Reputation
Reliability and Reputation
ISO 9001:2015

9001:2015

ISO 27001:2022

27001:2022

© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.